EDAP to Exclusively Distribute LABORIE’s Medical Measurement Systems Urodynamic Products in Japan
January 23 2017 - 7:30AM
EDAP TMS SA (NASDAQ:EDAP), the global leader in therapeutic
ultrasound, announced today that it has signed an exclusive
agreement with the Canadian company LABORIE to distribute their
urodynamic diagnostic products in Japan, one of the largest global
markets for urology.
Jean-François Bachelard, General Manager of EDAP TMS’s
subsidiary in Japan commented: "This agreement consolidates EDAP's
position as leader of the Urodynamic market in Japan. LABORIE’s
products will complement our lithotripsy range of products being
distributed by EDAP in Japan as it will provide our sales force
with an expanded urology focused product portfolio. We
will continue to capitalize on our well established direct
network to leverage its expertise and expand our market presence
across the country."
Wilfried Woesthuis, Director of International Sales for LABORIE,
added, "We are excited to expand our collaboration with EDAP’s
team. EDAP is very experienced in the Urodynamic field, the team is
highly skilled and motivated to support LABORIE’s existing large
customer base in Japan. In addition, EDAP will introduce new
revolutionary LABORIE products such as T-DOC air charged catheter
technology to the market. We are looking forward to our continued
fruitful cooperation."
Marc Oczachowski, EDAP TMS Chief Executive Officer, concluded:
"We are very pleased with this exclusive partnership with LABORIE
which continuously introduces innovative and rapidly adopted
devices and tools to markets. With LABORIE leading its specific
field of urology diagnosis and EDAP focusing on therapeutic urology
solutions, this agreement consolidates EDAP’s position as a leader
company in the urodynamic market in the Japanese territory."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters’ range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
About LABORIE
LABORIE was founded in 1967 by a pioneer in urodynamics, Ray
Laborie. Since then, LABORIE has expanded into new categories and
has established itself as a global leader in urology,
urogynecology, colorectal and gastroenterology. LABORIE takes great
pride in improving patients’ lives through innovations in pelvic
and gastrointestinal health. Founded by a visionary, today’s team
remains committed to developing, designing and distributing
next-generation solutions. Working closely with clinicians,
universities, and non-profits around the globe, we make a
difference worldwide. For more information on LABORIE, please visit
http://www.laborie.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management’s current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company’s filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company’s Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
CG CAPITAL
877.889.1972
investorrelations@cg.capital
www.cg.capital
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Apr 2023 to Apr 2024